Provided by Tiger Fintech (Singapore) Pte. Ltd.

Warrior Met Coal LLC

46.84
+0.06000.13%
Volume:228.85K
Turnover:10.65M
Market Cap:2.46B
PE:23.26
High:47.50
Open:47.25
Low:46.07
Close:46.78
Loading ...

Warrior Met Coal Inc : Bmo Cuts Target Price to $65 From $70

THOMSON REUTERS
·
16 Jan

Should You Increase Your Holdings in Warrior Met Coal (HCC)?

Insider Monkey
·
15 Jan

Warrior Met Coal, Inc. (HCC): A Bull Case Theory

Insider Monkey
·
15 Jan

NAYA Biosciences Announces Pricing of $9.5 Million Public Offering

GlobeNewswire
·
13 Jan

Warrior Met Coal (HCC) Gets a Hold from RBC Capital

TIPRANKS
·
10 Jan

Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials

GlobeNewswire
·
08 Jan

MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications

Business Wire
·
07 Jan

NAYA Biosciences Announces Development of NY-500, a Novel AI-Optimized PD-1 x VEGF Bifunctional Antibody

GlobeNewswire
·
06 Jan

Warrior Met Coal Is Maintained at Buy by Jefferies

Dow Jones
·
06 Jan

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

GlobeNewswire
·
06 Jan

Warrior Met Coal price target lowered to $65 from $75 at Jefferies

TIPRANKS
·
06 Jan

Are Investors Undervaluing Warrior Met Coal (HCC) Right Now?

Zacks
·
01 Jan

Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson

GlobeNewswire
·
30 Dec 2024

Investing in Warrior Met Coal (NYSE:HCC) five years ago would have delivered you a 175% gain

Simply Wall St.
·
28 Dec 2024

BullFrog AI Issues Letter to Stockholders

GlobeNewswire
·
27 Dec 2024

Warrior Met Coal (NYSE:HCC) Will Be Hoping To Turn Its Returns On Capital Around

Simply Wall St.
·
24 Dec 2024

Barington nominates Mitarotonda and two others as directors at Matthews, sources say

Reuters
·
19 Dec 2024

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

GlobeNewswire
·
18 Dec 2024